COMMUNIQUÉS West-GlobeNewswire

Medicus Pharma Receives Positive FDA Feedback and Central IRB Approval for Optimized Phase 2 Teverelix® Novel Study in Acute Urinary Retention
16/07/2026
Regulatory and ethical-review milestones advance a capital-efficient Phase 2 study expected to enroll ~126 patients versus ~390 under the previously disclosed development plan PHILADELPHIA, July 16, 2026 (GLOBE NEWSWIRE [...]
Former Smith+Nephew Global Orthopaedics President Craig Gaffin Joins MedEdge Holdings as Partner
16/07/2026
Healthcare industry veteran brings more than 25 years of commercial leadership experience to help expand MedEdge's platform for acquiring, building and commercializing innovative surgical technology companies GREENWICH [...]
Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders
16/07/2026
Arbutus and its exclusive licensee, Genevant, filed three international lawsuits seeking to enforce patents protecting their innovative lipid nanoparticle (“LNP”) technology against Pfizer and BioNTech Received [...]
Cronos Group Inc. to Hold 2026 Second Quarter Earnings Conference Call on August 6, 2026
16/07/2026
TORONTO, July 16, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) will hold its 2026 second quarter earnings conference call on Thursday, August 6, 2026 at 8:30 a.m. ET [...]
Madrigal Pharmaceuticals to Release Second-Quarter 2026 Financial Results and Host Webcast on July 30, 2026
16/07/2026
CONSHOHOCKEN, Pa., July 16, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its second-quarter 2026 financial results on Thursday, July 30, 2026, prior to the [...]
Relmada Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026
16/07/2026
CORAL GABLES, Fla., July 16, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central [...]
Plus Therapeutics and Genomic Testing Cooperative Partner to Integrate Next-Generation Sequencing Into the CNSide® CSF Assay Platform
16/07/2026
Collaboration expected to deliver hundreds of DNA and RNA biomarkers from a single CSF specimen — directly aligned with the updated NCCN Guidelines® (Version 2.2026), which now recognize CSF circulating tumor cells [...]
Theolytics Relocates to State-of-the-Art Facility at ARC Oxford to Drive Development of THEO-260 and Other Novel Oncolytic Immunotherapies
16/07/2026
Oxford UK, July 16th, 2026. Theolytics, a clinical-stage biotechnology company developing next-generation oncolytic immunotherapies, announces that it has relocated to new, state-of-the-art facilities at ARC Oxford, a [...]
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
16/07/2026
WATERTOWN, Mass., July 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, [...]
Diverge Health and Oakland Physician Network Services Announce Successful First-Year Partnership to Improve Quality of Care for Medicaid Patients in Michigan
16/07/2026
Deep clinical integration across 10 practices yields measurable improvements in quality outcomes and sets the stage for expanded shared savings and community health programming DETROIT, July 16, 2026 (GLOBE NEWSWIRE [...]
Greenwich LifeSciences Announces European Approval for Combining Both HLA Populations in FLAMINGO-01
16/07/2026
STAFFORD, Texas, July 16, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is [...]
Gain Therapeutics CEO Gene Mack Issues Letter to Shareholders and Provides Operational Update
16/07/2026
BETHESDA, Md., July 16, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of [...]
BrainsWay Announces Minority-Stake Investment in Sound Minds Behavioral
16/07/2026
Investment further supports BrainsWay's strategy of partnering with growth-oriented mental health providers to raise awareness and expand access to transformative care BURLINGTON, Mass. and JERUSALEM, July 16, 2026 ( [...]
Dyadic Expands Bio industrial Pipeline with New Proprietary Industrial Enzyme Program
16/07/2026
New initiative builds on EN3ZYME™ launch and highlights scalability of the Dapibus™ platform JUPITER, Fla., July 16, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (Nasdaq: DYAI) ("Dyadic" or the "Company"), d/b/a [...]
TerrAscend to Host Second Quarter 2026 Earnings Conference Call
16/07/2026
TORONTO, July 16, 2026 (GLOBE NEWSWIRE) -- TerrAscend Corp. (the “Company”) (TSX: TSND) (OTCQX: TSNDF) , a leading North American cannabis operator, today announced that it will host a scheduled conference call to [...]
New Review Examines Anatomical and Methodological Differences Between Auricular and Cervical Vagus Nerve Stimulation
16/07/2026
ROCKAWAY, N.J., July 16, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company and leader in non-invasive vagus nerve stimulation technologies, today [...]
Rinascera Therapeutics Launches with Clinical-Stage Pipeline to Transform the Treatment of Genetic Skin Diseases
16/07/2026
- Initial financing led by Double Point Ventures with participation from Olive Tree Capital, Civilization Ventures and Toba Capital - - Supports advancement of RIN-001 for Gorlin Syndrome and RIN-002 for Dystrophic [...]
Clearmind Medicine Reports Positive Retention Results for Intranasal Formulation of its Psychedelic-Based Neuroplastogen MEAI
16/07/2026
Vancouver, Canada, July 16, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), a clinical-stage biotechnology company pioneering non‑hallucinogenic neuroplastogen‑derived treatments for Alcohol Use [...]
Umoja Biopharma Announces FDA Clearance of IND Application for UB-VV400, the Industry’s First Known CD22-Directed In Vivo CAR T Cell Therapy for Relapsed/Refractory B Cell Malignancies
16/07/2026
The company’s lead internal program expands its in vivo CAR T clinical pipeline for patients with relapsed/refractory B cell malignancies First patient expected to be dosed in Q3 2026 SEATTLE, July 16, 2026 (GLOBE [...]

Pages